Skip to main content
Top
Published in: Clinical Rheumatology 2/2007

01-02-2007 | Original Article

Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA

Authors: Sumeet Agrawal, Ramnath Misra, Amita Aggarwal

Published in: Clinical Rheumatology | Issue 2/2007

Login to get access

Abstract

Introduction: Autoantibodies in rheumatoid arthritis (RA) are useful both for diagnosis and prognosis. Antibodies directed against citrullinated antigens have recently been shown to predict development of RA as well as poor outcome in early arthritis. Data on their role in established RA is limited. We studied the association of various autoantibodies in RA with its severity. Materials and methods: A total of one hundred and twenty nine-patients with established RA was enrolled and sera were collected and stored at −70°C. Data regarding erosions, deformities, and extra-articular features were collected. IgM rheumatoid factor (RF) was measured using nephelometry and value above 20 U was considered positive. IgA RF was measured by enzyme-linked immunosorbent assay (ELISA) and value above the mean±2 SD of normal healthy control was taken as positive. Anti-keratin antibody (AKA) was detected by indirect immunofluorescence assay using rat esophagus as substrate. Anti-cyclic citrullinated peptide (CCP) antibodies were measured by commercial ELISA and a value above 5 U was considered as positive. Results: The prevalence of various autoantibodies was: IgM RF 82.2%, anti-CCP antibodies 82.2%, AKA 51.9%, and anti IgA RF 45%. The concordance rate of anti-CCP antibodies with IgM RF was 83%, with AKA 68%, and with IgA RF 60.5%. All but one patient positive for AKA were positive for anti-CCP antibodies. The presence of IgM RF, AKA, and anti-CCP antibody was associated with joint erosions and deformities. None of the antibodies had any association with presence of extra-articular features. No association of IgA RF was seen with erosions, deformities, or extra-articular features. Among 23 seronegative RA patients, 11 were positive for anti-CCP antibodies and 6 were AKA positive. The presence of anti-CCP antibodies was associated with presence of deformities (p<0.05). Conclusion: Anti-CCP antibodies are present in majority of patients with established RA including seronegative patients. Both anti-CCP and AKA, in addition to conventional marker like IgM RF, are associated with severe erosive disease.
Literature
1.
go back to reference Combe B, Eliaou JF, Daurès JP, Meyer O, Clot J, Sany J (1995) Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 34:529–534PubMed Combe B, Eliaou JF, Daurès JP, Meyer O, Clot J, Sany J (1995) Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 34:529–534PubMed
2.
go back to reference van der Heijde DM, van Riel PL, van Leuween MA, van’t Hof MA, van Rijswijk MH, van de Putte LBA (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 31:519–525PubMed van der Heijde DM, van Riel PL, van Leuween MA, van’t Hof MA, van Rijswijk MH, van de Putte LBA (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 31:519–525PubMed
3.
go back to reference Meyer O, Combe B, Elias A, Benali K, Clot J, Sany J, Eliaou JF (1997) Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis 56:682–685PubMedCrossRef Meyer O, Combe B, Elias A, Benali K, Clot J, Sany J, Eliaou JF (1997) Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis 56:682–685PubMedCrossRef
4.
go back to reference Berthelot JM, Maugars Y, Castagnè A, Audrain M, Prost A (1997) Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled. Ann Rheum Dis 56:123–125PubMed Berthelot JM, Maugars Y, Castagnè A, Audrain M, Prost A (1997) Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled. Ann Rheum Dis 56:123–125PubMed
5.
go back to reference Kurki P, Aho K, Palosuo T, Heliovaara M (1992) Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede clinical disease. Arthritis Rheum 35:914–917PubMed Kurki P, Aho K, Palosuo T, Heliovaara M (1992) Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede clinical disease. Arthritis Rheum 35:914–917PubMed
6.
go back to reference Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific autoantibodies. J Clin Invest 101:273–281PubMed Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific autoantibodies. J Clin Invest 101:273–281PubMed
7.
go back to reference Westgeest AA, Boerbooms AM, Jongmans M, Vandenbroucke JP, Vierwinden G, van De Putte LB (1987) Antiperinuclear factor: indicators of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 14:893–897PubMed Westgeest AA, Boerbooms AM, Jongmans M, Vandenbroucke JP, Vierwinden G, van De Putte LB (1987) Antiperinuclear factor: indicators of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 14:893–897PubMed
8.
go back to reference Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M (1992) Antikeratin antibodies: diagnostic and prognostic markers of early rheumatoid arthritis. Ann Rheum Dis 51:743–746PubMed Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M (1992) Antikeratin antibodies: diagnostic and prognostic markers of early rheumatoid arthritis. Ann Rheum Dis 51:743–746PubMed
9.
go back to reference Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095CrossRefPubMed Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095CrossRefPubMed
10.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed
11.
go back to reference Bharadwaj A, Aggarwal Amita, Misra R (1999) Clinical relevance of IgA rheumatoid factor (RF) in children with juvenile rheumatoid arthritis. Rheumatol Int 19:47–49CrossRefPubMed Bharadwaj A, Aggarwal Amita, Misra R (1999) Clinical relevance of IgA rheumatoid factor (RF) in children with juvenile rheumatoid arthritis. Rheumatol Int 19:47–49CrossRefPubMed
12.
go back to reference Sharma BL, Rani R, Misra R, Aggarwal A (2000) Anti-keratin antibodies in patients with rheumatoid arthritis. Indian J Med Res 111:215–218PubMed Sharma BL, Rani R, Misra R, Aggarwal A (2000) Anti-keratin antibodies in patients with rheumatoid arthritis. Indian J Med Res 111:215–218PubMed
13.
go back to reference Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, Situnayake D, Gordon C, Buckley CD, Salmon M, Kitas GD (2005) Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32:231–238PubMed Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, Situnayake D, Gordon C, Buckley CD, Salmon M, Kitas GD (2005) Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32:231–238PubMed
14.
go back to reference Pruijn GJM, Vossenaar ER, Drijfhout JW, van Venrooij WJ, Zendman AJW (2005) Anti-CCP antibody detection facilitates early diagnosis and prognosis of rheumatoid arthritis. Curr Rheumatol Rev 1:1–7CrossRef Pruijn GJM, Vossenaar ER, Drijfhout JW, van Venrooij WJ, Zendman AJW (2005) Anti-CCP antibody detection facilitates early diagnosis and prognosis of rheumatoid arthritis. Curr Rheumatol Rev 1:1–7CrossRef
15.
go back to reference Vencovskỳ J, Machaèek S, Šedová L, Kafková J, Gatterová J, Pešáková V, Ruièková Š (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430CrossRefPubMed Vencovskỳ J, Machaèek S, Šedová L, Kafková J, Gatterová J, Pešáková V, Ruièková Š (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430CrossRefPubMed
16.
go back to reference Meyer O, Labarre C, Dougados M, Goupille Ph, Acntagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126PubMedCrossRef Meyer O, Labarre C, Dougados M, Goupille Ph, Acntagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126PubMedCrossRef
17.
go back to reference Furst DE (1994) Predictors of worsening clinical variables and outcomes in rheumatoid arthritis. Rheum Dis Clin North Am 20:309–319PubMed Furst DE (1994) Predictors of worsening clinical variables and outcomes in rheumatoid arthritis. Rheum Dis Clin North Am 20:309–319PubMed
18.
go back to reference Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, Daragon A, Tron F, Le Loet X (2003) Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 42:939–946CrossRef Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, Daragon A, Tron F, Le Loet X (2003) Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 42:939–946CrossRef
19.
go back to reference Teitsson I, Withrington RH, Seifert MH, Valdimarsson H (1984) Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor. Ann Rheum Dis 43:673–678PubMedCrossRef Teitsson I, Withrington RH, Seifert MH, Valdimarsson H (1984) Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor. Ann Rheum Dis 43:673–678PubMedCrossRef
20.
go back to reference Houssien DA, Choy EH, Carr AJ, Scott DL (1997) Rheumatoid arthritis (RA) outcome in routine practice: a comparison of outcome assessment. Arthritis Rheum 40:S152 (Suppl) Houssien DA, Choy EH, Carr AJ, Scott DL (1997) Rheumatoid arthritis (RA) outcome in routine practice: a comparison of outcome assessment. Arthritis Rheum 40:S152 (Suppl)
21.
go back to reference Eberhardt KB, Rydgren LC, Pettersson H, Wollheim FA (1990) Early rheumatoid arthritis—onset, course and outcome over 2 years. Rheumatol Int 10:135–142CrossRefPubMed Eberhardt KB, Rydgren LC, Pettersson H, Wollheim FA (1990) Early rheumatoid arthritis—onset, course and outcome over 2 years. Rheumatol Int 10:135–142CrossRefPubMed
22.
go back to reference Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680CrossRefPubMed Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680CrossRefPubMed
23.
go back to reference De Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate and extra-articular manifestatations. Ann Rheum Dis 63:1587–1593CrossRefPubMed De Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate and extra-articular manifestatations. Ann Rheum Dis 63:1587–1593CrossRefPubMed
Metadata
Title
Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA
Authors
Sumeet Agrawal
Ramnath Misra
Amita Aggarwal
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0275-5

Other articles of this Issue 2/2007

Clinical Rheumatology 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.